PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
14719131-1	2004	TAS-102 is a combination drug consisting of alpha,alpha,alpha-trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI).	tipiracil	126-129	THAS	Homo sapiens	0-3
34406678-1	2021	BACKGROUND: Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with refractory metastatic colorectal cancer (mCRC); limited comparative effectiveness data exist.	tipiracil	25-34	triosephosphate isomerase 1	Homo sapiens	40-43
11011219-4	2000	The basal level of total Proinsulin (tPI) of D and OI was significantly higher than that of C, but the tPI/Ins ratio did not differ between the five groups.	tipiracil	37-40	insulin	Homo sapiens	25-35
10889379-14	2000	Multivariate analysis identified pretreatment PSA > 10 ng/mL and Gleason score >6 as independent predictors for biochemical relapse after TPI.	tipiracil	144-147	kallikrein related peptidase 3	Homo sapiens	46-49
10945018-4	2000	TPI, an inhibitor of TP, suppresses growth and metastasis of tumors by inhibiting the effect of TP.	tipiracil	0-3	thymidine phosphorylase	Homo sapiens	21-23
2263469-8	1990	We have identified GRF1/RAPI/TUF-binding site positioned 339 to 349 bp 5" to the translation start of TPI.	tipiracil	102-105	DNA-binding transcription factor RAP1	Saccharomyces cerevisiae S288C	19-23
34848475-1	2021	BACKGROUND/AIM: Recently, trifluridine/tipiracil (FTD/TPI) treatment was established as a later-line treatment for metastatic colorectal cancer (mCRC).	tipiracil	39-48	triosephosphate isomerase 1	Homo sapiens	54-57
1409006-1	1992	Seven new antagonists of bombesin (Bn)/gastrin-releasing peptide (GRP) containing C-terminal Trp or Tpi (2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-carboxylic acid) in a reduced peptide bond were synthesized by solid phase methods and evaluated biologically.	tipiracil	100-103	gastrin releasing peptide	Mus musculus	39-64
1409006-1	1992	Seven new antagonists of bombesin (Bn)/gastrin-releasing peptide (GRP) containing C-terminal Trp or Tpi (2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-carboxylic acid) in a reduced peptide bond were synthesized by solid phase methods and evaluated biologically.	tipiracil	100-103	gastrin releasing peptide	Mus musculus	66-69
34175675-2	2021	In the TAGS study, trifluridine/tipiracil (FTD/TPI) improved overall survival (OS) compared with placebo in heavily pre-treated patients.	tipiracil	32-41	triosephosphate isomerase 1	Homo sapiens	47-50
34547581-1	2021	BACKGROUND: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI.	tipiracil	48-57	triosephosphate isomerase 1	Homo sapiens	63-66
34547581-1	2021	BACKGROUND: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI.	tipiracil	48-57	programmed cell death 1	Homo sapiens	209-240
34547581-1	2021	BACKGROUND: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI.	tipiracil	48-57	triosephosphate isomerase 1	Homo sapiens	376-379
34097100-1	2021	PURPOSE: Trifluridine/tipiracil (FTD/TPI) is approved for advanced colorectal and gastric/gastroesophageal cancer; however, data in patients with renal impairment (RI) are limited.	tipiracil	22-31	triosephosphate isomerase 1	Homo sapiens	37-40
34175675-2	2021	In the TAGS study, trifluridine/tipiracil (FTD/TPI) improved overall survival (OS) compared with placebo in heavily pre-treated patients.	tipiracil	32-41	Moloney sarcoma oncogene	Mus musculus	79-81
35182029-2	2022	Currently, molecular targeting agents and late-line treatment with regorafenib and trifluridine/tipiracil (FTD/TPI) are available.	tipiracil	96-105	triosephosphate isomerase 1	Homo sapiens	111-114
35050435-3	2022	Therefore, we investigated the efficacy of trifluridine/tipiracil (FTD/TPI) in patients with esophageal cancer who are refractory or intolerant to 5-fluorouracil, platinum-containing drugs, and taxanes.	tipiracil	56-65	triosephosphate isomerase 1	Homo sapiens	71-74
35278170-1	2022	BACKGROUND: Trifluridine/tipiracil (FTD/TPI) and irinotecan are treatment options for heavily pretreated patients with advanced gastric cancer, but their efficacies are limited.	tipiracil	25-34	triosephosphate isomerase 1	Homo sapiens	40-43
35474007-1	2022	INTRODUCTION: The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients.	tipiracil	105-114	triosephosphate isomerase 1	Homo sapiens	120-123
6316954-1	1983	The activation by thrombin of human platelets prelabelled with 32P induced a 30-40% decrease in 32P-triphosphoinositides (TPI) in the first 10 sec; the decrease in the other 32P-labelled phosphoinositides occurred by 20-30 sec.	tipiracil	122-125	coagulation factor II, thrombin	Homo sapiens	18-26
34997449-1	2022	BACKGROUND: Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study.	tipiracil	29-38	triosephosphate isomerase 1	Homo sapiens	44-47
35149429-1	2022	INTRODUCTION: Trifluridine/tipiracil (FTD/TPI) improved both overall and progression-free survival (OS, PFS) of patients with pre-treated metastatic colorectal cancer (mCRC) in the pivotal phase III RECOURSE trial.	tipiracil	27-36	triosephosphate isomerase 1	Homo sapiens	42-45
4084317-1	1985	Three different forms of thiol proteinase inhibitor (TPI) were isolated from newborn rat epidermis, in which two forms, TPI-1 and TPI-2, inhibited a proteinase activity, but another newly detected one (designated as TPI-3), showed no inhibitory effect.	tipiracil	53-56	triosephosphate isomerase 1	Rattus norvegicus	120-125
33569986-1	2021	Trifluridine/tipiracil (FTD/TPI) is an orally active formulation of trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
33993741-1	2021	Aim: To determine a recommended Phase II dose of the oral fluoropyrimidine trifluridine/tipiracil (FTD/TPI) combined with the multi-kinase inhibitor regorafenib (REG) in refractory metastatic colorectal cancer patients.	tipiracil	88-97	triosephosphate isomerase 1	Homo sapiens	103-106
33780084-1	2021	Trifluridine/tipiracil (FTD/TPI) is an orally administrated anticancer drug with efficacy validated for patients with metastatic colorectal cancer (mCRC) or gastric cancer.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
33464133-1	2021	Aim: To help to remove misperception of an appropriate position of trifluridine/tipiracil (FTD/TPI) in the treatment of metastatic colorectal cancer.	tipiracil	80-89	triosephosphate isomerase 1	Homo sapiens	95-98
33952483-1	2021	BACKGROUND/AIM: Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have have been shown to improve overall survival in patients with refractory metastatic colorectal cancer.	tipiracil	51-60	triosephosphate isomerase 1	Homo sapiens	66-69
33544407-2	2021	In MSS CRC xenograft models, trifluridine/tipiracil (FTD/TPI) plus programed death 1 inhibitors resulted in synergistic antitumor activity and increased tumor immunogenicity.	tipiracil	42-51	triosephosphate isomerase 1	Homo sapiens	57-60
33829029-9	2021	Targeting TYMP with tipiracil, a selective TYMP inhibitor, which has been approved by the Food and Drug Administration for clinical use, could be a novel effective medicine for COVID-19.	tipiracil	20-29	thymidine phosphorylase	Homo sapiens	10-14
33829029-9	2021	Targeting TYMP with tipiracil, a selective TYMP inhibitor, which has been approved by the Food and Drug Administration for clinical use, could be a novel effective medicine for COVID-19.	tipiracil	20-29	thymidine phosphorylase	Homo sapiens	43-47
33713215-2	2021	Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
33297751-3	2021	Tipiracil hydrochloride (TPI), a selective TYMP inhibitor, has been approved by the Food and Drug Administration for clinical use.	tipiracil	25-28	thymidine phosphorylase	Mus musculus	43-47
32962867-11	2021	Among the drugs, tipiracil and aprepitant interacted with the Mpro consistently, and they turned out to be most promising.	tipiracil	17-26	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	62-66
32371587-4	2020	Here, we propose a novel therapeutic strategy based on synthetic lethality combining trifluridine/tipiracil (FTD/TPI) and prexasertib (CHK1 inhibitor) as a treatment for ESCC.	tipiracil	98-107	triosephosphate isomerase 1	Homo sapiens	113-116
32816155-1	2020	PURPOSE: Trifluridine/tipiracil (FTD/TPI) improves the overall survival (OS) of metastatic colorectal cancer (mCRC) patients.	tipiracil	22-31	triosephosphate isomerase 1	Homo sapiens	37-40
32530932-1	2020	Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments.	tipiracil	35-44	triosephosphate isomerase 1	Homo sapiens	50-53
32891715-1	2020	Trifluridine/tipiracil (FTD/TPI; marketed as Lonsurf ) has shown clinically relevant activity after fluoropyrimidine failure in colorectal cancer and may thus be of increased efficacy compared with current standard capecitabine chemoradiation.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
33021466-1	2021	BACKGROUND: The RECOURSE trial (Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies) demonstrated an overall survival (OS) benefit of trifluridine/tipiracil (FTD/TPI) vs placebo in refractory metastatic colorectal cancer (mCRC).	tipiracil	196-205	triosephosphate isomerase 1	Homo sapiens	211-214
33173384-2	2020	The present study was initiated to address the lack of published prospective data about the qol benefits of trifluridine/tipiracil (ftd/tpi) compared with best supportive care (bsc) in patients with refractory metastatic colorectal cancer (mcrc).	tipiracil	121-130	triosephosphate isomerase 1	Homo sapiens	136-139
31826977-3	2020	Trifluridine/tipiracil (FTD/TPI) has activity in both fluoropyrimidine-sensitive and -resistant tumors, which led us to conduct a single arm phase II trial to evaluate the safety and efficacy of FTD/TPI for patients previously treated for advanced BTC.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
31826977-3	2020	Trifluridine/tipiracil (FTD/TPI) has activity in both fluoropyrimidine-sensitive and -resistant tumors, which led us to conduct a single arm phase II trial to evaluate the safety and efficacy of FTD/TPI for patients previously treated for advanced BTC.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	199-202
32348018-1	2020	Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents.	tipiracil	13-22	vascular endothelial growth factor A	Homo sapiens	289-323
31826977-1	2020	LESSONS LEARNED: Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors.FTD/TPI has an acceptable safety profile and should be studied further in patients with advanced biliary tract carcinoma after progression on standard first-line therapy.	tipiracil	30-39	triosephosphate isomerase 1	Homo sapiens	45-48
31826977-1	2020	LESSONS LEARNED: Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors.FTD/TPI has an acceptable safety profile and should be studied further in patients with advanced biliary tract carcinoma after progression on standard first-line therapy.	tipiracil	30-39	triosephosphate isomerase 1	Homo sapiens	216-219
32348018-1	2020	Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents.	tipiracil	13-22	epidermal growth factor receptor	Homo sapiens	340-372
32348018-5	2020	In the pivotal phase III RECOURSE trial evaluating trifluridine/tipiracil in chemotherapy-refractory mCRC, efficacy benefits were observed across all a priori prognostic subgroups including those defined by age (>=65 and >=75 years), geographical origin, primary tumor site or KRAS status.	tipiracil	64-73	KRAS proto-oncogene, GTPase	Homo sapiens	277-281
31838590-1	2020	BACKGROUND: Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes.	tipiracil	49-58	triosephosphate isomerase 1	Homo sapiens	64-67
30838483-0	2020	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.	tipiracil	72-81	5'-nucleotidase, cytosolic IIIA	Homo sapiens	156-161
31600365-1	2020	Importance: Trifluridine/tipiracil (FTD/TPI) treatment has shown clinical benefit in patients with pretreated metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC).	tipiracil	25-34	triosephosphate isomerase 1	Homo sapiens	40-43
30838483-2	2020	We conducted a phase I study to determine the maximum tolerated dose of oxaliplatin plus trifluridine/tipiracil (FTD/TPI) in patients with refractory mCRC.	tipiracil	102-111	triosephosphate isomerase 1	Homo sapiens	117-120
31591140-1	2020	BACKGROUND: Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC).	tipiracil	29-38	triosephosphate isomerase 1	Homo sapiens	46-49
31591140-12	2020	IMPLICATIONS FOR PRACTICE: Trifluridine plus tipiracil (FTD + TPI) and regorafenib (REG) prolong survival in refractory metastatic colorectal cancer (mCRC) but have different tolerability profiles.	tipiracil	45-54	triosephosphate isomerase 1	Homo sapiens	62-65
31611243-1	2019	Trifluridine/tipiracil (FTD/TPI) is a new antimetabolite agent used to treat chemorefractory metastatic colorectal cancer.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
30628113-1	2019	AIMS: Trifluridine/tipiracil (FTD/TPI) prolongs survival in refractory metastatic colorectal cancer, but limited data exist on its use in patients with hepatic impairment.	tipiracil	19-28	triosephosphate isomerase 1	Homo sapiens	34-37
32392174-1	2019	BACKGROUND: Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear.	tipiracil	56-65	triosephosphate isomerase 1	Homo sapiens	71-74
30257515-1	2018	Salvage chemotherapy for refractory metastatic colorectal cancer using trifluridine/tipiracil (FTD/TPI) and regorafenib has shown survival benefits.	tipiracil	84-93	triosephosphate isomerase 1	Homo sapiens	99-102
30350179-1	2018	PURPOSE: Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf ), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age.	tipiracil	22-31	triosephosphate isomerase 1	Homo sapiens	37-40
30172759-0	2018	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.	tipiracil	68-77	thymidine kinase 1	Homo sapiens	21-39
30172759-11	2018	CONCLUSION: Patients with high TK1 expression showed an improvement in OS when treated with FTD/TPI.	tipiracil	96-99	thymidine kinase 1	Homo sapiens	31-34
30445951-1	2018	BACKGROUND: Trifluridine/tipiracil (TAS-102, Lonsurf ), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies.	tipiracil	25-34	triosephosphate isomerase 1	Homo sapiens	238-241
29491068-1	2018	BACKGROUND/AIM: Trifluridine/tipiracil (FTD/TPI) is used for metastatic colorectal cancer, that is refractory to 5-fluorouracil (5-FU)-based therapies.	tipiracil	29-38	triosephosphate isomerase 1	Mus musculus	44-47
29568368-0	2018	Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.	tipiracil	13-22	thymidylate synthetase	Homo sapiens	107-127
29515409-1	2018	Trifluridine/tipiracil (FTD/TPI) significantly improves overall survival in patients with metastatic colorectal cancer (mCRC).	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
29568368-1	2018	Trifluridine/tipiracil (FTD/TPI or TFTD, also known as TAS-102) is a combination of the antineoplastic thymidine analog, FTD, and thymidine phosphorylase inhibitor, TPI (molar ratio 1:0.5).	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
29568368-1	2018	Trifluridine/tipiracil (FTD/TPI or TFTD, also known as TAS-102) is a combination of the antineoplastic thymidine analog, FTD, and thymidine phosphorylase inhibitor, TPI (molar ratio 1:0.5).	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	165-168
29312810-1	2017	Trifluridine/tipiracil (FTD/TPI or TFTD, also known as TAS-102) with a molar ratio of 1:0.5, is a novel combination of FTD, an antineoplastic thymidine analog, and TPI, an inhibitor of thymidine phosphorylase.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	28-31
29312810-1	2017	Trifluridine/tipiracil (FTD/TPI or TFTD, also known as TAS-102) with a molar ratio of 1:0.5, is a novel combination of FTD, an antineoplastic thymidine analog, and TPI, an inhibitor of thymidine phosphorylase.	tipiracil	13-22	triosephosphate isomerase 1	Homo sapiens	164-167
22563753-11	2012	Combination of TPI 1020 with a long-acting beta2-adrenoceptor agonist or muscarinic receptor antagonist may therefore be a more potent therapeutic approach for treatment of chronic respiratory diseases.	tipiracil	15-18	beta-2 adrenergic receptor	Cavia porcellus	43-61
29119052-1	2017	Trifluridine/tipiracil (FTD/TPI) is a combination of FTD, an antineoplastic thymidine-based nucleoside analog, and TPI, which acts to enhance the bioavailability of FTD in vivo.	tipiracil	13-22	triosephosphate isomerase 1	Mus musculus	28-31
29119052-1	2017	Trifluridine/tipiracil (FTD/TPI) is a combination of FTD, an antineoplastic thymidine-based nucleoside analog, and TPI, which acts to enhance the bioavailability of FTD in vivo.	tipiracil	13-22	triosephosphate isomerase 1	Mus musculus	115-118
26722024-4	2016	TAS-102 is a newly-developed anti-folate drug containing the 5-FU analogue trifluridine (TFD) and tipiracil hydrochloride (TPI).	tipiracil	123-126	THAS	Homo sapiens	0-3
25260740-2	2014	TPI has the interesting shape memory property by cross-linking, and this polymer was commercialized under the product name of SMP-2 (Kuraray Corp, Kashima, Japan).	tipiracil	0-3	lipin 3	Homo sapiens	126-131
23096484-9	2013	Examples are TPI ASM8, an inhaled anti-sense oligonucleotide drug product, which attenuated both early and LARs via inhibition of the target gene mRNA of chemokine receptor 3, and the common beta chain of interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor receptor.	tipiracil	13-16	C-X-C motif chemokine receptor 3	Homo sapiens	154-174
23096484-9	2013	Examples are TPI ASM8, an inhaled anti-sense oligonucleotide drug product, which attenuated both early and LARs via inhibition of the target gene mRNA of chemokine receptor 3, and the common beta chain of interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor receptor.	tipiracil	13-16	interleukin 5	Homo sapiens	220-233
28426271-7	2017	Significant factors associated with TPI efficacy were coexistence of cancer pain with MTrP at the pain site (odds ratio [OR]: 3.87, 95% CI: 1.21-12.4), MTrP at areas other than lower back or hip (OR: 6.45, 95% CI: 1.98-21.0), and fewer MTrPs (OR: 0.64, 95% CI: 0.42-0.99).	tipiracil	36-39	lysosomal protein transmembrane 4 alpha	Homo sapiens	86-90
28426271-7	2017	Significant factors associated with TPI efficacy were coexistence of cancer pain with MTrP at the pain site (odds ratio [OR]: 3.87, 95% CI: 1.21-12.4), MTrP at areas other than lower back or hip (OR: 6.45, 95% CI: 1.98-21.0), and fewer MTrPs (OR: 0.64, 95% CI: 0.42-0.99).	tipiracil	36-39	lysosomal protein transmembrane 4 alpha	Homo sapiens	152-156
21252618-9	2011	Thymidine phosphorylase inhibitor (TPI), 5-chloro-6-[1- (2-iminopyrrolidinyl) methyl] uracil hydrochloride reduce IgE production via blocking of STAT6- phosphorylation.	tipiracil	35-38	thymidine phosphorylase	Homo sapiens	0-23
21605124-1	2011	BACKGROUND: TPI ASM8 contains two modified antisense oligonucleotides (AON) targeting the beta subunit (beta(c) ) of the IL-3, IL-5, GM-CSF receptors and the chemokine receptor CCR3.	tipiracil	12-15	colony stimulating factor 2 receptor subunit beta	Homo sapiens	90-111
21605124-1	2011	BACKGROUND: TPI ASM8 contains two modified antisense oligonucleotides (AON) targeting the beta subunit (beta(c) ) of the IL-3, IL-5, GM-CSF receptors and the chemokine receptor CCR3.	tipiracil	12-15	interleukin 3	Homo sapiens	121-125
21605124-1	2011	BACKGROUND: TPI ASM8 contains two modified antisense oligonucleotides (AON) targeting the beta subunit (beta(c) ) of the IL-3, IL-5, GM-CSF receptors and the chemokine receptor CCR3.	tipiracil	12-15	colony stimulating factor 2	Homo sapiens	133-139
21605124-9	2011	Additionally, TPI ASM8 8 mg OD significantly attenuated the early and late airway responses as shown by the reduction in the area under the curve by 45% (P=0.016) and 59%, (P=0.0015), respectively, the increase in eosinophil cationic protein (ECP) by up to 57% (P=0.021), and airway responsiveness to methacholine by more than 1 doubling dose (P=0.012).	tipiracil	14-17	ribonuclease A family member 3	Homo sapiens	214-241
21605124-9	2011	Additionally, TPI ASM8 8 mg OD significantly attenuated the early and late airway responses as shown by the reduction in the area under the curve by 45% (P=0.016) and 59%, (P=0.0015), respectively, the increase in eosinophil cationic protein (ECP) by up to 57% (P=0.021), and airway responsiveness to methacholine by more than 1 doubling dose (P=0.012).	tipiracil	14-17	ribonuclease A family member 3	Homo sapiens	243-246
21252618-9	2011	Thymidine phosphorylase inhibitor (TPI), 5-chloro-6-[1- (2-iminopyrrolidinyl) methyl] uracil hydrochloride reduce IgE production via blocking of STAT6- phosphorylation.	tipiracil	35-38	signal transducer and activator of transcription 6	Homo sapiens	145-150
18600526-8	2008	L-deoxyribose (L-dR) and thymidine phosphorylase inhibitor (TPI) can reverse these effects.	tipiracil	60-63	thymidine phosphorylase	Homo sapiens	25-48
18844111-1	2008	OBJECTIVE: To explore the correlation of tip perfusion index (TPI) with the hemodynamics and catecholamines and to assess the value and meaning of TPI for monitoring stress responses in general anesthesia.	tipiracil	62-65	TOR signaling pathway regulator	Homo sapiens	41-44
17561925-3	2007	ir-coi1 plants are male sterile and impaired in JA-elicited direct [nicotine, caffeoylputrescine and trypsin proteinase inhibitor (TPI) activity] and indirect (cis-alpha-bergamotene emission) defense responses; responses not elicited by JA treatment (ethylene production and flower TPI activity) were unaffected.	tipiracil	131-134	coronatine-insensitive 1	Solanum lycopersicum	3-7
17561925-3	2007	ir-coi1 plants are male sterile and impaired in JA-elicited direct [nicotine, caffeoylputrescine and trypsin proteinase inhibitor (TPI) activity] and indirect (cis-alpha-bergamotene emission) defense responses; responses not elicited by JA treatment (ethylene production and flower TPI activity) were unaffected.	tipiracil	282-285	coronatine-insensitive 1	Solanum lycopersicum	3-7
17064784-2	2006	C3d index was significantly higher in anti-TPI-positive patient (n=5, median 0.446) than in anti-TPI-negative patient (n=7, median 0.098) (p=0.019) CSF samples.	tipiracil	43-46	endogenous retrovirus group K member 13	Homo sapiens	0-3
17064784-2	2006	C3d index was significantly higher in anti-TPI-positive patient (n=5, median 0.446) than in anti-TPI-negative patient (n=7, median 0.098) (p=0.019) CSF samples.	tipiracil	97-100	endogenous retrovirus group K member 13	Homo sapiens	0-3